We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An industy expert said last month that the advent of the Medicare drug benefit in 2006 could force drugmakers to move more aggressively into developing drugs similar to those already found in therapeutic categories.
The increased use of generic drugs will provide more significant cost savings to consumers than practices such as drug importation and price controls, a pair of reports issued by the federal government in late December 2004 indicate.
A federal court has blocked a provision in a Washington, D.C., prescription drug law that would have imposed fiduciary duties on pharmaceutical benefit managers (PBMs) and required them to disclose proprietary financial information negotiated with drugmakers.
The U.S.-Australia free trade agreement (FTA) was scheduled to take effect Jan. 1, even though U.S. officials are not satisfied with Australia’s implementing legislation that allows stiff penalties to be imposed against pharmaceutical patent holders ruled to have filed false or misleading certificates to extend patents.
A new rule requiring public firms to list stock options on financial statements will be particularly burdensome for biotechnology firms and could delay the development of breakthrough drugs for diseases such as cancer, diabetes and Alzheimer’s, according to the Biotechnology Industry Organization (BIO).
The increased use of generic drugs will provide more significant cost savings to consumers than practices such as drug importation and price controls, according to two government reports.
The pharmaceutical industry's primary methods of pricing products -- through intellectual property rights and diversity pricing, which allows firms to charge higher prices to those with greater ability to pay -- are under attack, a free-market think tank concludes in a new paper opposing drug importation proposals.
A new accounting rule requiring companies to list stock options on financial statements will be particularly burdensome for biotechnology firms and could delay the development of breakthrough drugs for diseases such as cancer, diabetes and Alzheimer’s, according to the Biotechnology Industry Organization (BIO).
Spending on pharmaceutical R&D could fall as much as 40 percent if the government were to leverage its buying power under the Medicare Modernization Act (MMA) to force down drug prices, contends a new study by a public policy think tank.
Similar drugs that follow a breakthrough product into a therapeutic class can provide clinical and economic benefits, according to pharmaceutical experts who rebutted arguments that so-called me-too drugs divert R&D resources from true innovation.